Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse - Episode 3

Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

, , , ,

Panelists discuss the CEPHEUS trial results for newly diagnosed patients who are not transplant eligible, highlighting key takeaways. They also compare the CEPHEUS data with other quadruplet regimens in the non–transplant-eligible space, such as Isa-VRd.

EP. 1: Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates
EP. 2: Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma
Now Viewing
EP. 3: Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies
EP. 4: MRD Negativity as a Trial Outcome and Its Use in Clinical Practice
EP. 5: Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma
EP. 6: Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

Dr Ajai Chari to Dr Callander: Switching to those newly diagnosed patients who are not transplant eligible or for whom transplant is not planned as initial therapy, Dr Callander, can you summarize the CEPHEUS data results presented at IMS and your key takeaways from this trial?

Resource Links

Dr Ajai Chari to Dr Martin: How do CEPHEUS data compare to other quadruplet regimens in the non–transplant-eligible space, like Isa-VRd?

Resource Link

Resource Link:

Related Content:

Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse
Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma
Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
MRD Negativity as a Trial Outcome and Its Use in Clinical Practice